Navigation Links
First results from hospital trials testing
Date:10/28/2008

NEW YORK, NY (October 28, 2008) The first stage of the U.S. Department of Defense-funded clinical trials exploring the role of hospital touch surfaces in the transmission of infectious pathogens has been completed and the researchers reported their findings in a poster session at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. on Tuesday, October 28. The data presented describe the first results of a three phase study where the bioload found on stainless steel, plastic and aluminum objects in intensive care unit rooms were measured. Phases two and three of the study are ongoing. During these phases, the bioload on identical objects made of microbiocidal copper will be measured to determine the effectiveness of copper at combating hospital-acquired infections.

The findings being presented at ICAAC show that the most heavily contaminated objects are those in closest proximity to the patients: bed rails, call buttons and chairs were found to have the highest levels of staphylococcus, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). These pathogens can survive for extended periods of time on such objects, which act as reservoirs for the bacteria.

Independent laboratory studies have shown that copper, brass and bronze are more than 99.9 percent effective in killing potentially deadly pathogens, such as MRSA, which are commonly found in healthcare facilities. In response to these findings, the Environmental Protection Agency has registered copper, brass and bronze as antimicrobial materials, allowing public health claims to be made about them.

A similar clinical trial is also being conducted at Selly Oak Hospital, University Hospital Birmingham in the U.K. Results from this trial, also being presented at ICAAC, show a 90-95 percent reduction in contamination on copper alloy surfaces compared to the controls.


'/>"/>

Contact: Geralyn Lederman
glederman@kellencompany.com
212-297-2118
Copper Development Association
Source:Eurekalert

Page: 1

Related biology news :

1. Which came first, the moth or the cactus?
2. First all-African GM crop is resistant to maize streak virus
3. Scientists retrace evolution with first atomic structure of an ancient protein
4. CU-Boulder team discovers first ancient manioc fields in Americas
5. First finding of a metabolite in 1 sex only
6. First orchid fossil puts showy blooms at some 80 million years old
7. First individual genome sequence published
8. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
9. UNH becomes first university in nation to use landfill gas as primary energy source
10. Scientists in first global study of poison gas in the atmosphere
11. Weight gain between first and second pregnancies associated with increased odds of male second child
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology: